



Daniel M Aebersold

Contact

Daniel M Aebersold

Publications (16)

Beck M, Li Q, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti D, Reuter C, Gomez S, Khanfir K, Aebersold D, Ghadjar P, Schär C, Hayoz S, Papachristofilou A, Sassowsky M, Schär S, Mathier E, Halter M, Zwahlen D, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller A, Putora P, Pra A. Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. *Int J Radiat Oncol Biol Phys* 2022; 113:80-91.

Ghadjar P, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti D, Kaouthar K, Gomez S, Wust P, Thalmann G, Aebersold D, Sumila M, Schär C, Hayoz S, Bernhard J, Zwahlen D, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller A, Plasswilm L, Papachristofilou A, Swiss Group for Clinical Cancer Research (SAKK). Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. *Eur Urol* 2021; 80:306-315.

Achard V, Matzinger O, Peguret N, Pesce G, Putora P, Reuter C, Richetti A, Veas H, Vrieling C, Zaugg K, Zimmermann F, Zwahlen D, Tsoutsou P, Kaouthar K, Huck C, Herrmann E, Aebersold D, Allal A, Andratschke N, Baumert B, Beer K, Betz M, Breuneval T, Bodis S, De Bari B, Förster R, Franzetti-Pellanda A, Guckenberger M, Zilli T. A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: Present changes and future perspectives. *Radiother Oncol* 2020; 150:1-3.

Elicin O, Giger R, Spielmann T, Prestwich R, Riesterer O, Kaydihan N, Shelan M, Guckenberger M, Ozsahin M, Anschuetz L, Adam L, Henke G, Studer G, Zimmermann F, Caparrotti F, Aebersold D, Oehler C, Ermiş E, Şen M. Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer-A Multicenter Study. *Front Oncol* 2019; 9:932.

Plasswilm L, Studer G, Aebersold D, Zwahlen D. [Modern Treatment Concepts in Radiation Oncology]. *Ther Umsch* 2019; 76:209-218.

Hoyle A, Aebersold D, Jones R, Matheson D, Millman R, Mason M, Ritchie A, Russell M, Douis H, Parmar M, Sydes M, Clarke N, Gillissen Sommer S, Ingleby F, Ali A, James N, Cook A, Parker C, de Bono J, Attard G, Chowdhury S, Cross W, Dearnaley D, Brawley C, Gilson C, STAMPEDE Investigators. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. *Eur Urol* 2019; 76:719-728.

Riesterer O, Kraysenbuehl J, Weder W, Sabrina Stark L, Zimmermann F, Nackaerts K, Zwahlen D, Mahmut Ozsahin E, Plasswilm L, Aebersold D, Xyrafas A, Stahel R, Ciernik I, Swiss Group for Clinical Cancer Research (SAKK). Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. *Radiother Oncol* 2019; 138:121-125.

Elicin O, Broglie M, Fankhauser N, Stoeckli S, Pasche P, Reinhard A, Bongiovanni M, Huber G, Morand G, Soltermann A, Arnold A, Dettmer M, Arnoux A, Stauffer E, Espeli V, Martucci F, Aebersold D, Giger R. Comparison of contemporary staging systems for oropharynx cancer in a surgically treated multi-institutional cohort. *Head Neck* 2018; 41:1395-1402.

Panje C, Lupatsch J, Plasswilm L, Aebersold D, Siano M, Gautschi O, Schwenkglenks M, Matter-Walstra K, Dedes K, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). *Radiother Oncol* 2018; 129:257-263.

Cihoric N, Aebersold D, Yojena C, Soldatovic I, Shelan M, Scherz A, Novak U, Glatzer M, Vlaskou Badra E, Tsikkinis A, Lössl K. Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study. *Radiat Oncol* 2017; 12:202.

Ghadjar P, Thalmann G, Aebersold D, Wust P, Biaggi Rudolf C, Dal Pra A, Schär C, Papachristofilou A, Putora P, Müller A, Hildebrandt G, Polat B, Gut P, Hölscher T, Stein J, Zwahlen D, Bernhard J, Hayoz S, Swiss Group for Clinical Cancer Research (SAKK). Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. *Radiother Oncol* 2017

Ghadjar P, Kranzbühler H, Najafi Y, Ost P, Azinwi N, Reuter C, Bodis S, Kaouthar K, Budach V, Aebersold D, Thalmann G, Sumila M, Biaggi-Rudolf C, Stalder L, Hayoz S, Genitsch V, Zwahlen D, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller A, Putora P, Papachristofilou A, Swiss Group for Clinical Cancer Research (SAKK). Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer. *BJU Int* 2017; 120:E45-E51.

Elicin O, Giger R, Ghadjar P, Geretschlager A, Plasswilm L, Ambarcioglu P, Rauch D, Bromme J, Schmücking M, Aebersold D. Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma: a retrospective analysis. *J BUON* 2016; 21:175-81.

Stahel R, Caspar C, Eckhardt K, Schmid R, Aebersold D, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L, Mordasini C, Zippelius A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. *Lancet Oncol* 2015; 16:1651-8.

Panje C, Panje T, Putora P, Kim S, Haile S, Aebersold D, Plasswilm L. Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience. *Radiat Oncol* 2015; 10:47.

Sassowsky M, Takacs I, Reuter C, Sumila M, Manser P, Ost P, Böhmer D, Pilop C, Aebersold D, Plasswilm L, Azinwi N, Zwahlen D, Gut P, Hölscher T, Hildebrandt G, Müller A, Najafi Y, Kohler G, Kranzbühler H, Guckenberger M, Ghadjar P. Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10. *Int J Radiat Oncol Biol Phys* 2013; 87:534-41.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch